Geron Corporation to Present at Bank of America Health Care Conference
MENLO PARK, Calif., May 12, 2008 – Geron Corporation (Nasdaq: GERN) today announced that David L. Greenwood., executive vice president and chief financial officer, will present an update of the company’ s product development programs at 2:00 p.m. PDT on Tuesday, May 13, 2008, at the Bank of America 2008 Health Care Conference in Las Vegas.
The update of Geron’ s portfolio of telomerase-based anti-cancer therapies will include the inhibitor drug, GRN163L, and the therapeutic vaccine, GRNVAC1. Additionally, the presentation will include reviews of the company’ s human embryonic stem cell development programs for spinal cord injury (GRNOPC1), heart disease (GRNCM1) and diabetes (GRNIC1).
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell-based therapeutics, with its spinal cord injury treatment anticipated to be the first product to enter clinical development. For more information, visit www.geron.com.
CONTACTS:
Media and Investors: David Schull, Russo Partners, LLC, 858-717-2310,
david.schull@russopartnersllc.com
At Geron: David L. Greenwood, Chief Financial Officer, 650-473-7765, info@geron.com
